Latent Labs Emerges from Stealth with $50M to Advance AI-Driven Drug Discovery
Slice of Healthcare Team
Feb 19, 2025
Key Highlights
- Latent Labs exits stealth with $50M total funding, including a $40M Series A co-led by Radical Ventures and Sofinnova Partners.
- Founded by Dr. Simon Kohl, former co-lead of DeepMind’s protein design team and key contributor to AlphaFold2.
- Investors include Google Chief Scientist Jeff Dean, Transformer architecture inventor Aidan Gomez, and ElevenLabs founder Mati Staniszewski.
- Latent Labs' AI platform enables de novo protein design, expediting drug development and unlocking new therapeutic targets.
- Operates in London and San Francisco, combining AI innovation with in-lab experimental validation.
Source: Business Wire
Notable Quotes
“ Every biotechnology or pharmaceutical company wants to be at the forefront of technology to find the best therapeutic molecules, yet not all are in a position to develop the most advanced AI models for the job. That's where Latent Labs comes in. ”
Dr. Simon Kohl, CEO & Founder at Latent Labs
“ We’ve partnered with Latent Labs because we’re confident that this team will realize the therapeutic and commercial potential of de novo protein design. Such a capability has never before been possible, one which can benefit humanity in such a profound way. ”
Aaron Rosenberg, Partner at Radical Ventures
“ Latent Labs transforms biology from an observational science into an engineering craft, granting us precise control over life’s building blocks. ”
Edward Kliphuis, Partner at Sofinnova Partners
Why This Matters
AI-driven generative biology therapeutic and industrial applications custom molecules accelerate drug development, improve treatment success rates, and unlock new avenues for precision medicine redefine biotechnology and pharmaceutical innovation
